Please login to the form below

Not currently logged in
Email:
Password:

QVA149

This page shows the latest QVA149 news and features for those working in and with pharma, biotech and healthcare.

Boehringer bags FDA approval for Spiriva-based combo

Boehringer bags FDA approval for Spiriva-based combo

Competition is only expected to increase further in COPD. For example, Novartis is due to enter the US LAMA/LABA category shortly with its QVA149 (glycopyrronium bromide/indacaterol) product, which is

Latest news

  • Novartis files COPD combo in US Novartis files COPD combo in US

    Novartis files COPD combo in US. QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist. ... Novartis is hoping new data from its pivotal clinical trial programmes will help position QVA149 in the market.

  • FDA approves Boehringer COPD spray Striverdi Respimat FDA approves Boehringer COPD spray Striverdi Respimat

    But there is a lot of potential competition in COPD at present, including Novartis' QVA149 (glycopyrronium bromide and indacaterol maleate) and GSK and Theravance's Anoro (umeclidinium bromide and vilanterol).

  • Novartis, Boehringer stake claims to combination COPD market Novartis, Boehringer stake claims to combination COPD market

    Ultibro (formerly QVA149) was the first LAMA/LABA to be approved for marketing in the EU, while rival product Anoro (umeclidinium bromide and vilanterol) from GlaxoSmithKline was the first drug in

  • Novartis' combo COPD inhaler cleared in EU Novartis' combo COPD inhaler cleared in EU

    Ultibro (formerly QVA149) combines the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide with the long-acting beta agonist (LABA) indacaterol, which are already approved as monotherapies in the EU as Seebri

  • FDA queries safety of GSK's Anoro for COPD FDA queries safety of GSK's Anoro for COPD

    GSK will find the COPD market increasing competitive, however, with a panoply of other new COPD combinations coming through the pipeline, including Boehringer Ingelheim/Pfizer's olodaterol/tiotropium, Novartis' QVA149 (glycopyrronium

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics